Entellus Medical Inc., which is developing a less-invasive therapy to treat chronic sinusitis, has hired a new chief executive.
Brian Farley, who has served on the company’s board since 2008 and previously led VNUS Medical Technologies Inc., takes over the CEO job from Entellus co-founder Tom Ressemann, according to a company statement.
Ressemann will stay on as Entellus’ chief business development officer.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Farley joined VNUS, which developed a catheter-based treatment for venous insufficiency, in 1995 as its first employee. During his time as CEO, the company went public in 2004 and was acquired last year for $440 million by medical-products giant Covidien Ltd.
Entellus’ FinESS sinus treatment is designed to relieve the need for antibiotics or invasive surgery to treat chronic sinusitis. The company says its treatment reduces a patient’s recovery time, because it doesn’t require removing bone or sinus tissue and can be done with minimal bleeding. The procedure is performed by inserting a balloon catheter into a patient’s nasal cavity through a tiny incision under the lip, then expanding the balloon in the passageway and draining excess mucus from the sinus.
In November, Entellus closed a $30 million round of funding that was led by new investor Essex Woodlands Health Ventures and supported by existing investors Split Rock Partners and SV Life Sciences. The company has raised $57 million overall.
